Keywords
bile duct diseases
biochemistry
Lavafam
Abstract
Liver damage is a common problem all over the world. To optimize the drug provision in the limited financing of the Health Care System, it is necessary to develop new drugs with hepatoprotective properties that are highly effective and of low cost. That is why we developed the original drug Lavaflam. Lavaflam is a combination of the following substances: dry concentrate of Helichrysum arenarium and Lavender oil. The purpose of the research was to assess the biochemical evidence of the hepatoprotective properties of the drug Lavaflam on the experimental model of subchronic hepatitis in rats. Construction of an experimental model of subchronic hepatitis in rats, comparison of hepatoprotective properties of Lavaflam and Carsil preparations on the basis of biochemical research.
The subject of the study was to determine the hepatoprotective properties of Lavaflam tablets. Experimental subchronic hepatitis induced in rats by way of intragastrical introduction of tetrachlormethane. The study drug Lavaflam in this experimental model of subchronic tetrachlormethane hepatitis in rats showed a positive effect on oxidant processes by increasing the compensatory mechanisms of antioxidant systems; inhibiting free radical pathology; having positive effect on the processes of biliary excretion, cholestasis, reduction of infiltrative, destructive and inflammatory process in the liver; decreasing the cytolytic process; restoring the structure of the membrane components of hepatocytes; stabilizing and enhancing functional activity of the liver; restoring its protein-synthetic function; and increasing the ability of the drug Lavaflam to restore metabolic and liver damage.
As a result of the performed biochemical study of the hepatoprotective action of Lavaflam, it has been found that in the developed drug Lavaflam, the level of hepatoprotective action corresponds with the reference drug Carsil.
References
1. Chalasani N, Younossi Z, Lavine J, Diehl AM, Brunt E, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases. American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005-23.
2. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterol. 2015;148:547-55.
3. Habior A. Diseases of the liver of a threat in Europe in the twenty-first century. Achievements in the Field of Medical Sciences. 2009;2: 1977-83.
4. Petri A, Sabin K. Visual statistics in medicine. Moscow: Geotar-Media; 2003. p. 143.
5. Aslanian MA, Bobrytska L, Goncharov МІ, Nazarova ES, Popova NV, Litvinenko VI. Medicinal product of choleretic effect № u201409419. Patent 97298 Ukraine, MPК А 61 К 36/53. bulletin №5.
6. Aslanyan M, Bobrytska L, Hrytsenko V, Shpychak O, Popova N, Germanyuk T, et al. Technological aspects of development of a new drug in tablets called “Lavaflam” and its pharmaco-economic evaluation. Res J Pharm Bioll Chem Sci. 2017;4(8):808-14.
7. Stefanov OV. Preclinical research of medicines. Moscow: Geotar Media; 2001. p.528.
8. Rikalo NA. Experimental model of chronic tetrachloromethane hepatitis and liver cirrhosis in non-pregnant rats. Bull Ukr Med Stomatol Acad. 2009;9;116-8.
9. European convention for the protection of vertebrate animals used for experimental and other scientific purposes. European Treaty Series - No. 123. Strasbourg: Council of Europe; 1986.
10. Abrashova TV, Gushchin YaA, Kovaleva MA, Rybakova AV, Selezneva AI, Sokolova AP, Hodko SV. Preclinical studies. Directory physiological, biochemical and biometric indices of the norm of experimental animals. Moscow: Geotar Media; 2013. p. 118.
11. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Amer J Clin Path. 1957;28:56.
12. Reference book for clinical and biochemical research and laboratory diagnostics. Medpressinform; 2009.
13. Severina ES. Biochemistry. Moscow: Geotar Media; 2003.
14. Chevari S, Chaba I, Sekeĭ I. The role of superoxide dismutase in the oxidative processes of the cell and the method for its determination in biological materials. Lab Delo. 1985;11:678-81.
15. Nishiki M, Rao NA, Yagi K. The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen. Biochem. Biophys Res Com. 1972;46:849-54.
16. Kamishnikov VS. Reference book for clinical and biochemical research and laboratory diagnostics. Moscow: Medpressinform; 2009.
17. Abrashova TV, Gushchin YaA, Kovaleva MA, Rybakova AV, Selezneva AI, Sokolova AP, Hodko SV. Preclinical studies. Background Physiological, Biochemical and Biometric Indices of the Experimental Animals' Standard. 2013;118.
18. Harutyunyan AB, Dubinina EE, Zybinka IM. Methods of estimation of free radical processes in an organism: methodical recommendations. Foliant. 2000;103.
19. Stalnaya ID, Garishvili TG. Method for the determination of malondialdehyde with tiobarbituric acid/ID. in ed. Orehovich VN. (ed) Modern Methods in Biochemistry. 1977. p.66-68.
20. Kamyshnikov VS. Handbook on Clinical-Biochemical Laboratory Diagnostics. 2003;495.
21. Skoy NY. Chronic diseases of the biliary tract. Pathogenesis and laboratory diagnostics. 1972;229.
22. Rebrova OY. Statistical analysis of medical data. Application of the application package Statistica. Moscow: Mediasfera Publ; 2006.
23. Ivko T, Aslanian M, Bobrytska L, Popova N, Nazarova O, Bereznyakova N, Germanyuk Т. Development of the composition and manufacturing technology of a new combined drug: Lavaflam. Turk J Pharm Sci. 2018;15(3):263-270
24. Aslanian MA, Bobrytska LA, Bereznyakova NL, Shpychak OS, Hrytsenko VІ, Germanyuk TA, Ivko TI. Histological research of hepatoprotective activity of tablets Lavaflam in rats with subchronic hepatitis. Zaporozhye Med J. 2018;2:182-187.
25. Arakelyan MA, Bobrytska LO, Popova NV. Marketing research of the market of drugs with the choleretic action. News of Pharmacy. 2014;2:63-67.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2020 Autors